An updated safety review of the drug treatments for idiopathic pulmonary fibrosis

References

• Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Collard H, Jones M. Idiopathic Pulmonary Fibrosis. Published Online First Lancet. 2017;38910082:1941–1952.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44–68.
   PubMed Web of Science ®Google Scholar
• Cordier J-F, Cottin V. Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur Respir J. 2013;42(4):916–923.
   PubMed Web of Science ®Google Scholar
• Raghu G, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977. Published Online First.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.
   PubMed Web of Science ®Google Scholar
• Hirano A, Kanehiro A, Ono K, et al. Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am J Respir Cell Mol Biol. 2006;35(3):366–377.
   PubMed Web of Science ®Google Scholar
• Conte E, Gili E, Fagone E, et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–19.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253.
   PubMed Web of Science ®Google Scholar
• Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–1445.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–1047.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–829.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769. Published Online First.
   PubMed Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22): 2083–2092. .
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016;71(5):429–435.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Lancaster LH, Albera C, et al. Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. BMJ Open Respir Res. 2018;5(1):1–9.
   Web of Science ®Google Scholar
• Costabel U, Albera C, Lancaster LH, et al. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration. 2017;94(5):408–415.
   PubMed Web of Science ®Google Scholar
• Costabel U, Albera C, Glassberg MK, et al. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):2–5.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Costabel U, Albera C, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019;153:44–51.
   PubMed Web of Science ®Google Scholar
• Cottin V, Koschel D, Günther A, et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res. 2018;4(4):00084–2018.
   PubMedGoogle Scholar
• Lancaster L, Albera C, Bradford WZ, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. 2016;3(1):1–7.
   Web of Science ®Google Scholar
• Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med. 2013;107(9):1431–1437.
   PubMed Web of Science ®Google Scholar
• Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration. 2014;88(3):199–207.
   PubMed Web of Science ®Google Scholar
• Hanta I, Cilli A, Sevinc SC. The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: a Retrospective Study. Adv Ther. 2019;36(5):1126–1131.
   PubMed Web of Science ®Google Scholar
• Yoon H-Y, Kim DS, Song JW. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis. Respiration. 2019;97(3):242–251.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Ntolios P, Karampitsakos T, et al. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: a real-world observational study. Pulm Pharmacol Ther. 2017;46:48–53.
   PubMed Web of Science ®Google Scholar
• Galli JA, Pandya A, Vega-Olivo M, et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017;22(6):1171–1178.
   PubMed Web of Science ®Google Scholar
• Krauss E, Tello S, Wilhelm J, et al. Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: long-Term, Real-World Data from European IPF Registry (eurIPFreg). J Clin Med. 2020;9(11):3763.
   Web of Science ®Google Scholar
• Tzouvelekis A, Karampitsakos T, Ntolios P, et al. Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. Front Med. 2017;4:1–7.
   Web of Science ®Google Scholar
• Dhooria S, Agarwal R, Sehgal IS, et al. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis, Vasc Diffus Lung Dis off J WASOG. 2020;37:148–157.
   PubMed Web of Science ®Google Scholar
• Song MJ, Moon SW, Choi JS, et al. Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. Sci Rep. 2020;10(1):1–8.
   PubMed Web of Science ®Google Scholar
• Eaden JA, Barber CM, Renshaw SA, et al. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study. Sarcoidosis, Vasc Diffus Lung Dis off J WASOG. 2020;37:218–224.
   PubMed Web of Science ®Google Scholar
• Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–157.
   PubMed Web of Science ®Google Scholar
• Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016;43(9):1672–1679.
   PubMed Web of Science ®Google Scholar
• Lancaster LH, De Andrade JA, Zibrak JD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26(146):170057.
   PubMed Web of Science ®Google Scholar
• Acharya N, Sharma SK, Mishra D, et al. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial. Rheumatol Int. 2020;40(5):703–710.
   PubMed Web of Science ®Google Scholar
• Mateos-Toledo H, Mejía-Ávila M, Ó Ó, et al. An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis. Arch Bronconeumol. 2020;56(3):163–169.
   PubMed Web of Science ®Google Scholar
• Gotfried MH, Girod CE, Antin-Ozerkis D, et al. An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002). Pulm Ther. 2018;4(1):59–71.
   PubMedGoogle Scholar
• Fang C, Huang H, Guo J, et al. Real-world experiences: efficacy and tolerability of pirfenidone in clinical practice. PLoS One. 2020;15(1):1–15.
   Web of Science ®Google Scholar
• Tzouvelekis A, Karampitsakos T, Kontou M, et al. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study in Greece. Pulm Pharmacol Ther. 2018;49:61–66.
   PubMed Web of Science ®Google Scholar
• Tzilas V, Tzouvelekis A, Bouros E, et al. Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. ERJ Open Res. 2020;6(4):00152–2020.
   PubMedGoogle Scholar
• Richeldi L, Costabel U. Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis Luca. N Engl J Med. 2011;365(12):1079–87.
   PubMed Web of Science ®Google Scholar
• Noth I, Wijsenbeek M, Kolb M, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Eur Respir J. 2019;54(3):1801797.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–79.
   PubMed Web of Science ®Google Scholar
• Wind S, Schmid U, Freiwald M, European Medicines Agency. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019;58(9):1131–1147.
   PubMed Web of Science ®Google Scholar
• Marzin K, Kretschmar G, Luedtke D, et al. Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment. J Clin Pharmacol. 2018;58(3):357–363.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Assessment report OFEV. EMA/315975/2020 2020;31.
   Google Scholar
• Richeldi L, Fletcher S, Adamali H, et al. No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone. Eur Respir J. 2019;53(1):1–11.
   Web of Science ®Google Scholar
• Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193(2):178–185.
   PubMed Web of Science ®Google Scholar
• Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60–68. Published Online First.
   PubMed Web of Science ®Google Scholar
• Wuyts WA, Kolb M, Stowasser S, et al. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value. Lung. 2016;194(5):739–743.
   PubMed Web of Science ®Google Scholar
• Kolb M, Raghu G, Wells AU, et al. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018;379(18):1722–1731.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Kolb M, Jouneau S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;4:1–8.
   Google Scholar
• Maher TM, Stowasser S, Nishioka Y, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019;7(9):771–779.
   PubMed Web of Science ®Google Scholar
• Morisset J, Johannson KA, Jones KD, et al. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. Am J Respir Crit Care Med. 2018;197(8):1036–1044.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73(6):581–583.
   PubMed Web of Science ®Google Scholar
• Lancaster L, Ilowite J, Trampisch M, et al. Effect of nintedanib on disease progression: results from a phase IIIB trial in patients with idiopathic pulmonary fibrosis. In Nashville, TN, USA Poster Present Pulm Fibros Found. 2017.
   Google Scholar
• Lancaster L, Crestani B, Hernandez P, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6(1):1–7.
   Web of Science ®Google Scholar
• Bonella F, Kreuter M, Hagmeyer L, et al. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration. 2016;92(2):98–106.
   PubMed Web of Science ®Google Scholar
• Toellner H, Hughes G, Beswick W, et al. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clin Transl Med. 2017;6(1):41.
   PubMed Web of Science ®Google Scholar
• Harari S, Caminati A, Poletti V, et al. A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis. Respiration. 2018;95(6):433–440.
   PubMed Web of Science ®Google Scholar
• Brunnemer E, Wälscher J, Tenenbaum S, et al. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Respiration. 2018;95(5):301–309.
   PubMed Web of Science ®Google Scholar
• Noth I, Oelberg D, Kaul M, et al. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. Eur Respir J. 2018;52(1):1702106.
   PubMed Web of Science ®Google Scholar
• Barratt SL, Mulholland S, Al Jbour K, et al. South-West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Front Pharmacol. 2018;9:1480.
   PubMed Web of Science ®Google Scholar
• Fletcher SV, Jones MG, Renzoni E, et al. Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis – initial clinical experience in a UK cohort. Thorax. 2015;70(A78): LP–ALP–A78.
   Google Scholar
• Hughes G, Toellner H, Morris H, et al. Real World Experiences: pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. J Clin Med. 2016;5(9):78.
   PubMed Web of Science ®Google Scholar
• Proesmans VLJ, Drent M, Elfferich MDP, et al. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients. Lung. 2019;197(5):551–558.
   PubMed Web of Science ®Google Scholar
• Denneny EK, Vekaria G, Sahota J, et al. P55 Bleeding risk in patients with idiopathic pulmonary fibrosis (IPF) on nintedanib and con-current anticoagulation or antiplatelet therapy. Thorax. 2019;74: A119LP–A119.
   Web of Science ®Google Scholar
• Sugino K, Nakamura Y, Sekiya M, et al. Fatal diffuse alveolar haemorrhage mimicking acute exacerbation in idiopathic pulmonary fibrosis treated with nintedanib. Respirol case reports. 2017;5(6):e00258.
   Google Scholar
• Lasky JA, Criner GJ, Lazarus HM, et al. Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: global Pharmacovigilance Data. Adv Ther. 2020;37(10):4209–4219.
   PubMed Web of Science ®Google Scholar
• Cameli P, Refini RM, Bergantini L, et al. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: a Real-Life Comparison Study. Front Mol Biosci. 2020;7:1–8 .
   Google Scholar
• Cerri S, Monari M, Guerrieri A, et al. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a 24-month assessment. Respir Med. 2019;159:2–7.
   Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Diseases IL. N Engl J Med 2019:1–10. doi:https://doi.org/10.1056/nejmoa1908681
   Google Scholar
• Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases — subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial : a randomised, double-blind. Lancet Resp Med. 2020;2600:1–8.
   Google Scholar
• Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1382–1392.
   PubMed Web of Science ®Google Scholar
• Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197(3):356–363.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Fell CD, Huggins JT, et al. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J. 2018;52(2):1–10.
   Web of Science ®Google Scholar
• European Medicines Agency. Pirfenidone - summary of product characteristics. Evid Eur Asylum Proced. 2011. doi:https://doi.org/10.1163/9789004219991_012
   Google Scholar
• Milger K, Kneidinger N, Neurohr C, et al. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur Respir J. 2015;46(4):1217–1221.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25–33. Published Online First.
   Web of Science ®Google Scholar
• Maher TM, Van Der Aar EM, Van De Steen O, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018;6(8):627–635.
   PubMed Web of Science ®Google Scholar
• Raghu G, Van Den Blink B, Hamblin MJ, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis a randomized clinical trial. J Am Med Assoc. 2018;319(22):2299–2307.
   PubMed Web of Science ®Google Scholar